Address: Lauchefeld 31, CH-9548 Matzingen, Switzerland
Tel: +41 52 366 3520
Fax: +41 52 366 3521

IBR Inc., Institute for Biopharmaceutical Research

IBR Inc. is a GLP certified service provider near Zürich that supports its customers from preclinical R&D through to clinical Phase III. We are specialized in being able to develop and optimise complex methods from scratch such as Elisa’s, in vitro enzyme activity assays and cell based assays (potency, migration, adhesion, proliferation assays etc.) After method development we can perform the method validations according to GLP and perform sample analysis in preclinical and clinical samples.

IBR Inc. has been GLP compliant since 2001 and was last inspected by Swissmedic (Swiss regulatory authorities) in April 2011.

Cell Based Assays:
  • Development and validation of different cell proliferation migration, adhesion assays for recombinant proteins or biomarker
  • Human PBMC assays: Proliferation assay, Biomarker expression, Isolation of subpopulations by magentic beads, validation of preclinical data prior to start of the clinical studies with cell based assays using human PBMC
  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  • Cytotoxic T lymphocytes (CD3−CD8+CTL) and natural killer (NK) cells (CD16+)
  • Opsonophagocytosis assay (OPA) for antibody dependant cytotoxicity
  • Recombinant Cytokines: Determination of bioactivity in cell based assays
  • PK/PD analysis of large molecules (antibodies, proteins) in animal and human samples (method development, validation sample analysis) according to GLP
  • Anti-Drug-Antibody assay in animal and human samples (method development, validation sample analysis) according to GLP
  • Neutralising antibodies testing
  • New draft FDA guideline on quantitation according to size of residual DNA >200bp in the final vaccine drug product per DNA size
  • Clinical Study Vaccines: Cellular immunology and functional in vitro tests
  • Vaccines activation of innate system
  • Biomarker expression (RNA/Protein) in fluids, tissue sections, biopsies
  • Bioactivity of cytokine
  • Medical Devices: Development of a haemolytic assay
  • Enzyme activity and kinetic test development, optimization and validation and sample analysis
  • Enzyme inhibitors assay (IC50), method development ,validation and sample analysis
  • Tissue cross-reactivity (TCR) studies by Immunohistochemistry (IHC) for cross reactivity studies to determine off-target binding and on-target binding
  • In situ Hybridization studies for Biomarker expression
Partnering Opportunity:
IT Software: in house developments in a GLP compliant laboratory
  • Check&Track™: Pipette Calibration and Management Software
  • Weigh&Track™: Weighing Software to document weighing in real time according to GxP

To learn more about IBR's services and capabilities and how they can assist your business, please contact IBR directly.

Follow us on:
Follow Us Networking
  • Drug Discovery
  • Pre-Clinical Research